(PDF) P2.03-17 EGFR T790M Mutation May Not Be Generated

P2.03-17 EGFR T790M Mutation May Not Be Generated Through Selection by EGFR-TKI From Randomly Occurring Mutations in Vitro Using ENU

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1204

Full Text

Open PDF

Abstract

Available in full text

Date

October 1, 2018

Authors

Y. Kobayashi

T. Mitsudomi

Publisher

Elsevier BV

Related search

P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance

Journal of Thoracic Oncology

English

The EGFR T790M Mutation Is Acquired Through AICDA-mediated Deamination of 5-Methylcytosine Following TKI Treatment in Lung Cancer.

Cancer Research

Oncology

2018

English

P2.03-016 Clinical Utility of Liquid Biopsy for Detecting EGFR T790M Mutation Is Very Limited

Journal of Thoracic Oncology

English

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics

Cancer Research

Oncology

2016

English

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management

2020

English

Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer

English

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

Journal of Thoracic Oncology

English

P2.03-10 Gene Mutational Profiling of Chinese TKI-Sensitizing EGFR Mutations NSCLC Patients Required Resistance to Icotinib Using NGS

Journal of Thoracic Oncology

English

Amanote Research

P2.03-17 EGFR T790M Mutation May Not Be Generated Through Selection by EGFR-TKI From Randomly Occurring Mutations in Vitro Using ENU

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1204

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance

The EGFR T790M Mutation Is Acquired Through AICDA-mediated Deamination of 5-Methylcytosine Following TKI Treatment in Lung Cancer.

P2.03-016 Clinical Utility of Liquid Biopsy for Detecting EGFR T790M Mutation Is Very Limited

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

P2.03-10 Gene Mutational Profiling of Chinese TKI-Sensitizing EGFR Mutations NSCLC Patients Required Resistance to Icotinib Using NGS